StockData
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Generate Biomedicines, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)

Close on Oct 19, 2026

Market cap
$1.61B
P/E (TTM)
–
Dividend yield
–

Generate Biomedicines, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Generate Biomedicines does not break out revenue by segment, region or product in the tagged data of its filings for this period type.